“By integrating a sales function, Kappa increases its overall competitiveness with the ability to work more closely with customers and partners,” Kappa said in a statement.
The move expands its bone an heart health offerings beyond vitamin K2 to calcium, magnesium and vitamin D3.
Last year Kappa bought Synthetica AS – “another long-term partner specialising in drug and vitamin synthesis, analysis, and research and development.”
Kappa said it was now in “full ownership of the value chain, from development through production to finished formulations.”
CEO Egil Greve said the firm was now proficient in areas from “molecule development and production via R&D to finished formulation or dosage format.’’